22157.jpg
Gene Therapy Market Study 2019 | World Market Set to Witness a CAGR of 18.7% During 2019-2024
December 09, 2019 05:23 ET | Research and Markets
Dublin, Dec. 09, 2019 (GLOBE NEWSWIRE) -- The "Gene Therapy Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.The Global Gene...
Neubase_Logo_RGB_Black.png
NeuBase Therapeutics Initiates Trading on NASDAQ Under Ticker Symbol “NBSE”
July 15, 2019 10:20 ET | NeuBase Therapeutics, Inc.
PITTSBURGH, July 15, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next generation antisense therapies to...
Neubase_Logo_RGB_Black.png
NeuBase Therapeutics Closes Merger Transaction with Ohr Pharmaceutical
July 12, 2019 09:28 ET | NeuBase Therapeutics, Inc.
Company expects to initiate trading on NASDAQ Under Ticker Symbol “NBSE” effective July 15, 2019Company completes previously announced financing of approximately $9 million immediately prior to...
ohrlogo.jpg
Ohr Pharmaceutical, Inc. Announces Stockholder Approval of Merger Agreement with NeuBase Therapeutics, Inc.
July 10, 2019 13:03 ET | Ohr Pharmaceutical, Inc.
NEW YORK, July 10, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (“Ohr”) (Nasdaq: OHRP) today announced that all proposals related to its proposed merger with NeuBase Therapeutics, Inc....
ohrlogo.jpg
Ohr Pharmaceutical Urges Stockholders to Vote “FOR” Merger with NeuBase Therapeutics at Special Meeting on July 10, 2019
July 03, 2019 10:00 ET | Ohr Pharmaceutical, Inc.
-- Of the Votes Received to Date, More than 99% Are Voting in Favor of the Merger Proposal-- More Votes Are Needed to Reach 50% of the Outstanding Shares to Go Forward with the Special Meeting-- Every...
NeuBase_Final_jpg.jpg
NeuBase Therapeutics Designates Industry Leaders to Board of Directors 
May 16, 2019 08:00 ET | NeuBase Therapeutics, Inc.
PITTSBURGH, May 16, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today...
ohrlogo.jpg
Ohr Pharmaceutical Reports Financial Results for the Fiscal Second Quarter of 2019
May 15, 2019 16:01 ET | Ohr Pharmaceutical, Inc.
NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three and six month periods ended March 31, 2019....
RL Logo.jpg
Rigrodsky & Long, P.A. Files Class Action Suit Against Ohr Pharmaceutical, Inc.
April 09, 2019 23:00 ET | Rigrodsky & Long, P.A.
WILMINGTON, Del., April 09, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.: Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court...
NeuBase_Final_jpg.jpg
NeuBase Therapeutics Announces Agreements for $9 Million Financing
March 11, 2019 07:00 ET | NeuBase Therapeutics, Inc.
PITTBURGH, Pa., March 11, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address rare genetic diseases,...
ohrlogo.jpg
Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements
February 21, 2019 10:45 ET | Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company has regained...